Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Anna Wilder

Physician Assistant Richmond, VA Physician Assistant

NPI 1013514892 CMS profile 10715429

1800 Glenside Dr Ste 101, Richmond, VA 23226

Open in the dashboard

General payments

$8,431

479 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Wilder of Richmond, VA is reported in the CMS Open Payments database as having received $8,431 across 479 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,718 91
2024 General $2,462 128
2023 General $1,406 80
2022 General $1,497 95
2021 General $1,348 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Wilder
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Anna Wilder were reported at $1,718. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Anna Wilder Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,348 $132 $37–$438 $132
2022 $1,497 $155 $48–$522 $149
2023 $1,406 $167 $52–$557 $160
2024 $2,462 $178 $55–$600 $164
2025 $1,718 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,230 78 payments
  2. Lilly USA, LLC $661 39 payments
  3. AstraZeneca Pharmaceuticals LP $656 26 payments
  4. Amgen Inc. $603 40 payments
  5. Pfizer Inc. $564 34 payments
  6. AbbVie, Inc. $548 39 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $528 32 payments
  8. Abbott Laboratories $491 22 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $233 15 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $206 13 payments
  11. Other $2,710 141 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,417 478 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $933 59 payments
  2. RYBELSUS $822 51 payments
  3. FARXIGA $497 17 payments
  4. MOUNJARO $384 21 payments
  5. FreeStyle Libre 3 $376 15 payments
  6. NURTEC ODT $371 22 payments
  7. BREZTRI $327 9 payments
  8. ZEPBOUND $315 17 payments
  9. JARDIANCE $314 19 payments
  10. UBRELVY $303 20 payments
  11. Other $6,844 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

773

Median for Physician Assistant: 241

Drug cost

$21,920

Median for Physician Assistant: $4,110

Branded share of claims

14.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 13 $12,738
Tramadol Hcl Generic 26 $1,494
Synthroid Levothyroxine Sodium Brand 25 $1,416
Atorvastatin Calcium Generic 78 $611
Zolpidem Tartrate Er Zolpidem Tartrate Brand 17 $456
Rosuvastatin Calcium Generic 21 $380
Potassium Chloride Generic 19 $337
Omeprazole Generic 16 $325
Levothyroxine Sodium Generic 30 $296
Sertraline Hcl Generic 40 $275

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$38,502

Of which drugs: $7,197

Medicare patients

180

Average age 74

Services billed

1,301

144 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 49%
Depression 29%
Chronic kidney disease 19%
Osteoporosis 19%
Cancer 18%
Diabetes 17%
Ischemic heart disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 18 18 $1,473

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 37 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $92
  • Boehringer Ingelheim Pharmaceuticals, Inc. $67
$159 — —
ZEPBOUND
  • Lilly USA, LLC $115
$115 — —
RYBELSUS
  • Novo Nordisk Inc $104
$104 — —
Ozempic
  • Novo Nordisk Inc $104
$104 13 —
NURTEC ODT
  • PFIZER INC. $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 37 with Patron

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record